Lilly, BI Get Tentative FDA Approval for Insulin Basaglar as an NDA

Generic Line
A A
Eli Lilly and Boehringer Ingelheim have won tentative FDA approval for their insulin product Basaglar, which is considered the biosimilar of a Sanofi product in Europe but is being reviewed as its own NDA in the United States.

To View This Article:

Login

Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00